Published in Cancer Weekly, October 11th, 2005
"Exatecan is a hexacyclic topoisomerase-1 inhibitor that has broad in vitro and in vivo activity. A multicenter phase II study to determine the antitumor activity of exatecan was conducted in patients with advanced cholangiocarcinoma and gallbladder carcinoma. Patients with 0 to 1 prior chemotherapy regimens, adequate major organ function, and metastatic disease were eligible," scientists reported in the American Journal of Clinical Oncology - Cancer Clinical Trials.
"Exatecan was administered at a dose of .5 mg/m2 IV over 30...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.